Provectus Pharmaceuticals Inc. | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Provectus Pharmaceuticals Inc.

An SI Board Since April 2006

Posts	SubjectMarks	Bans	Symbol
13111	103	0	PVCT

Emcee: Jack Russell	Type: Moderated

Introduction Market Data Compact

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
11386	which disease stage and progression rate did they study? How soon you forget tha	NTTG	1	6/27/2012
11385	The better it gets, the longer your posts NTTG... SIGNS OF FRUSTRATION? ah ah.	jm2i123	2	6/27/2012
11384	the bystander effect is less interesting in phase III patients? Honestly? You	Mammon	2	6/27/2012
11383	you are not sure that pv10 would do better than a comparator arm of DTIC. Reee	Mammon	3	6/27/2012
11382	Before we get to a discussion of possible market size the more pressing question	NTTG	2	6/27/2012
11381	Based on the final phase 2 data and the proposed phase 3 study would you say tha	LT2011	-	6/27/2012
11380	Our blogster friend posted some interesting positive observations re PV-10's	Howard Williams	-	6/27/2012
11379	Senate Passes FDA Bill Expected To Generate $6 Billion In Fees and Speed Approva	boomertree2	5	6/27/2012
11378	Looks like the proposed study population dropped from ~300 to ~180 subjects beca	NTTG	1	6/27/2012
11377	I did...guess you didn't read the rest of the post.	NTTG	1	6/26/2012
11376	hostile? I don't know what you mean. I expect better posts from you. Whe	Mammon	2	6/26/2012
11375	didn't take any drugs before my surgery...caught it early enough that surger	NTTG	1	6/26/2012
11374	for the same reason men take a drug to lower their testosterone and shrink their	Mammon	2	6/26/2012
11373	stage III? Why wouldn't a dermatologist simply excise an early lesion, recu	NTTG	1	6/26/2012
11372	Its interesting, the extraordinary OR in phase III patients. One could make a	Mammon	1	6/26/2012
11371	sorry the results didn't turn out the way you wanted, what can I say	NTTG	1	6/26/2012
11370	No, yours sounds like a spitball analysis.	Mammon	3	6/26/2012
11369	Yea, I saw that. But disease control is not what the FDA is looking for, and in	NTTG	1	6/26/2012
11368	I think the Stage III results are VERY impressive ........... 81% disease contro	Howard Williams	2	6/26/2012
11367	Two years to lock the database...amazingly slow for 80 patients. Gotta wonder w	NTTG	2	6/26/2012
11366	Top Line Final Data For Phase 2 marketwatch.com	LT2011	-	6/26/2012
11365	Particularly since he hopefully was presenting data that PVCT provided analysis	NTTG	1	6/25/2012
11364	Nice report in Lancet online on dabrafenib vs dicarbazine for patients with pre-	NTTG	1	6/25/2012
11363	Beats me, LT. And I wonder how our blogster friend established that we'll s	Howard Williams	-	6/25/2012
11362	Something intrigues me, Howard. What did Dr Agarwala talk about/reveal in his p	LurkeyTurkey	-	6/25/2012

Go to reply# or date (mm/dd/yy):